同步与异时转移性肾细胞癌:转移时间对靶向治疗预后的影响
基于IMDC数据库7386例一线TKI治疗的mRCC患者,比较同步转移(初诊≤3个月内)与异时转移(>3个月至>7年不同间隔)的OS和TTF。结果显示转移时间越晚,OS和TTF越好,同步转移预后最差,多因素校正后趋势仍显著。
要点
- 同步转移患者OS中位16.7个月,异时转移各间隔组分别为23.8、30.2、34.8和41.7个月。
- 转移时间>2-7年和>7年者OS风险比分别为0.74和0.60,TTF风险比分别为0.83和0.66。
- 同步转移患者更多具有高T分期、N1、肉瘤样分化、IMDC poor risk等不良因素。
核心结论
- 初始肾癌诊断后转移发生的时间越晚,靶向治疗下的OS和TTF越好,同步转移预后最差。
研究设计与样本
- 回顾性分析国际转移性肾细胞癌数据库联盟(IMDC)中7386例一线TKI治疗的mRCC患者。
- 同步转移定义为初诊≤3个月内出现转移,异时转移按>3-12个月、>1-2年、>2-7年和>7年间隔分组。
主要发现
- 同步转移3906例(53%),异时转移3480例(47%)。
- 同步转移组高T分期(T1-2:19% vs 34%)、N1(21% vs 6%)、肉瘤样分化(15.8% vs 7.9%)、KPS<80(25.9% vs 15.1%)、贫血(62.5% vs 42.3%)、中性粒细胞升高(18.9% vs 10.9%)、血小板升高(21.6% vs 11.4%)、骨转移(40.4% vs 29.8%)和IMDC poor risk(40.6% vs 11.3%)比例更高。
- 同步转移 vs 异时转移各间隔(>3-12个月、>1-2年、>2-7年、>7年)的TTF中位分别为5.6 vs 7.3、8.0、10.8和13.3个月(p<0.0001)。
- 同步转移 vs 异时转移各间隔的OS中位分别为16.7 vs 23.8、30.2、34.8和41.7个月(p<0.0001)。
- 多因素校正后OS的HR(95%CI)依次为1.00(参照)、0.98(0.90-1.06)、0.81(0.73-0.91)、0.74(0.68-0.81)和0.60(0.54-0.67)(p<0.0001);TTF的HR依次为1.00(参照)、0.99(0.92-1.06)、0.98(0.90-1.07)、0.83(0.77-0.89)和0.66(0.60-0.72)(p<0.0001)。
临床怎么用
- 评估mRCC患者预后时可将转移时间(同步或异时及间隔长短)作为分层因素。
- 同步转移患者不良因素负荷更高,应加强治疗监测和随访。
局限性
- 数据为回顾性收集。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with metastatic renal cell carcinoma (mRCC) may present with primary metastases (synchronous disease) or develop metastases during follow-up (metachronous disease). The impact of time to metastasis on patient outcome is poorly characterised. OBJECTIVE: To characterise overall survival (OS) and time to treatment failure (TTF) based on time to metastasis in mRCC patients treated with targeted therapy (tyrosine kinase inhibitors [TKIs]). DESIGN, SETTING, AND PARTICIPANTS: We used the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) to compare synchronous (metastases within ≤3 mo of initial diagnosis of cancer) versus metachronous disease (evaluated by >3-12 mo, >1-2 yr, >2-7 yr, and >7 yr intervals). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: OS and TFF were assessed using Kaplan-Meier curves. Cox multivariable regressions analyses (MVAs) were adjusted for baseline factors. RESULTS AND LIMITATIONS: Of 7386 patients with mRCC treated with first-line TKIs, 3906 (53%) and 3480 (47%) had synchronous and metachronous metastasis, respectively. More patients with synchronous versus metachronous disease had higher T stage (T1-2: 19% vs 34%), N1 disease (21% vs 6%), presence of sarcomatoid differentiation (15.8% vs 7.9%), Karnofsky performance status <80 (25.9% vs 15.1%), anaemia (62.5% vs 42.3%), elevated neutrophils (18.9% vs 10.9%), elevated platelets (21.6% vs 11.4%), bone metastases (40.4% vs 29.8%), and IMDC poor risk (40.6% vs 11.3%). Synchronous versus metachronous disease by intervals >3-12 mo, >1-2 yr, >2-7 yr, and >7 yr correlated with poor TTF (5.6 mo vs 7.3, 8.0, 10.8, and 13.3 mo, p < 0.0001) and poor OS (median 16.7 mo vs 23.8, 30.2, 34.8, and 41.7 mo, p < 0.0001). In MVAs, the adjusted hazard ratios (95% confidence intervals) were 1.00 (reference), 0.98 (0.90-1.06), 0.81 (0.73-0.91), 0.74 (0.68-0.81), and 0.60 (0.54-0.67), respectively, for OS (p < 0.0001), and 1.00 (reference), 0.99 (0.92-1.06), 0.98 (0.90-1.07), 0.83 (0.77-0.89), and 0.66 (0.60-0.72), respectively, for TTF (p < 0.0001). Data were collected retrospectively. CONCLUSIONS: Timing of metastases after initial RCC diagnosis may impact the outcomes from targeted therapy in mRCC. PATIENT SUMMARY: We looked at the impact of the timing of metastatic outbreak on survival outcomes in kidney cancer patients treated with targeted therapy. We found that the longer time to metastatic development was associated with improved outcome.
引用
- Donskov F, Xie W, Overby A, et al. Synchronous Versus Metachronous Metastatic Disease: Impact of Time to Metastasis on Patient Outcome-Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol Oncol. 2020. PMID: 32037304. doi:10.1016/j.euo.2020.01.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。